Acute lower gastrointestinal (GI) bleeding occurs distally to the ligament of Treitz. This article focuses on bleeding isolated to the colon and rectum. Lower GI bleeding has an incidence of 20 to 30 cases per 100,000 person years and accounts for 20% of GI bleeds. It requires admission to the hospital in 20 to 30 per 100,000 patients and has a mortality rate of 4%. The differential diagnosis for lower GI bleeding includes multiple conditions (Table 1). Diverticular disease is the most common source of lower GI bleeding, accounting for 40% of cases. The incidence of initial episodes of diverticular bleeding is 11 per 100,000 person years. The incidence increases with age, comorbidities (e.g., cardiovascular disease, cirrhosis, renal disease, diabetes mellitus, malignancy), and the use of antiplatelet medications, including nonsteroidal anti-inflammatory drugs. Hemorrhoids (internal and external) are another common source of lower GI bleeding, although the prevalence of this condition and its incidence of bleeding are not well established. Hemorrhoids are most common among patients 45 to 65 years of age. Other sources of lower GI bleeding have a wide range of incidence, preventing a clear hierarchy of differential presentations. It should be noted that upper GI bleeding presents similarly to lower GI bleeding (specifically, hematochezia) in 15% of cases.

Evaluation

OUTPATIENT EVALUATION

Initial outpatient evaluation of lower GI bleeding should focus on the patient’s history (specifically, the character of bleeding, change in bowel habits, course of symptoms, quantity of bleeding, and risk of recent bacterial exposures from food or travel) and physical examination (Figures 1 and 2). Further evaluation should be based on the suspected etiology of bleeding.

Hemorrhoidal bleeding typically presents with bright red blood noted on toilet paper, the surface of the stool, or in the toilet bowl after a bowel movement. It rarely causes anemia.
Bloody diarrhea followed by acute lower:
Slow, chronic blood loss with occasional
going (e.g., cautery, banding, clipping, epinephrine injection) to control bleeding
Consider abdominal CTA to localize the bleeding site
Fiber supplementation (decreases bleeding by 50%); banding or infrared photocoagulation for grades I to III; surgery likely required for symptomatic grade III and grade IV
Antibiotics based on identified pathogen, except for Shiga toxin–producing Escherichia coli and Salmonella, which are treated with supportive care alone
Fecal calprotectin ≥ 250 mcg per g
Rectal 5-aminosalicylic acid derivatives (e.g., mesalamine)
Colonoscopy or CTA to confirm diagnosis
Medical management of underlying vascular disease; may require surgery
Colonoscopy with endoscopic therapy (e.g., cautery, banding, clipping, epinephrine injection) to control bleeding
Consider long-term treatment with lanreotide (Somatuline), 120 mg subcutaneously every 4 weeks (adjust dosing for patients with renal or hepatic impairment)
Colonoscopy with endoscopic argon plasma coagulation

Differential Diagnosis and Treatment of Acute Lower Gastrointestinal Bleeding

<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>Distinguishing features</th>
<th>Evaluation and treatment</th>
</tr>
</thead>
</table>
| Angiodysplasia, angioectasias, or arteriovenous malformation | Recurrent painless bleeding episodes; patient > 60 years                                | Colonoscopy with endoscopic argon plasma coagulation
Consider long-term treatment with lanreotide (Somatuline), 120 mg subcutaneously every 4 weeks (adjust dosing for patients with renal or hepatic impairment) |
| Colon cancer                                        | Slow, chronic blood loss with occasional changes in bowel habit                         | Colonoscopy with endoscopic therapy (e.g., cautery, banding, clipping, epinephrine injection) to control bleeding
Referral to surgical and oncologic specialists |
| Diverticular bleeding                                | Acute, severe, painless bleeding; history of or suspected diverticular disease          | Colonoscopy with endoscopic therapy to control bleeding
Consider abdominal CTA to localize the bleeding site |
| Hemorrhoids                                          | Bleeding associated with bowel movements External: painful and itchy Internal: painless, may be itchy | Fiber supplementation (decreases bleeding by 50%); banding or infrared photocoagulation for grades I to III; surgery likely required for symptomatic grade III and grade IV |
| Infectious colitis                                   | Bloody diarrhea with fever; new or concerning food exposures                          | Antibiotics based on identified pathogen, except for Shiga toxin–producing Escherichia coli and Salmonella, which are treated with supportive care alone |
| Inflammatory bowel disease                           | Bloody diarrhea associated with recurrent abdominal pain and weight loss                | Colonoscopy with biopsies to confirm diagnosis
Fecal calprotectin ≥ 250 mcg per g
Rectal 5-aminosalicylic acid derivatives (e.g., mesalamine) |
| Ischemic colitis                                     | Bloody diarrhea followed by acute lower abdominal pain, especially in patients with cardiac risk factors | Colonoscopy or CTA to confirm diagnosis
Medical management of underlying vascular disease; may require surgery |
| Postpolypectomy bleeding                              | Bleeding within 30 days of polypectomy or biopsy                                        | Colonoscopy with endoscopic therapy to control bleeding |

Note: Colonoscopy should always be preceded by adequate bowel preparation.

CTA = computed tomographic angiography.

Adapted with permission from Wilkins T, Baird C, Pearson AN, et al. Diverticular bleeding. Am Fam Physician. 2009;80(9):978, with additional information from references 2, 7, 8, and 10-12.

External (originating below the dentate line) hemorrhoids are often painful and itchy, whereas internal (originating above the dentate line) hemorrhoids are nonpainful but may still be itchy. Patients younger than 40 years in whom hemorrhoidal bleeding is suspected do not require endoscopy unless they present with red flag symptoms (e.g., weight loss, fever, anemia, personal or family history of colon cancer, nonresponse to medical management). Evaluation is best accomplished by direct visualization using an anoscope while the patient performs the Valsalva maneuver.

Bleeding from infectious colitis presents with acute onset of bloody diarrhea associated with recent travel or consumption of foods concerning for bacterial exposure (Table 2). Stool cultures should be obtained to isolate the offending pathogen and to guide antibiotic therapy. Patients with recent travel to tropical Africa, Asia, or Latin America should also undergo testing for Entamoeba histolytica, which is endemic to those areas.

Bleeding from angiodysplasia is recurrent and painless. It is more common in people older than 60 years. These patients should be referred for diagnostic colonoscopy.

Inflammatory bowel disease (IBD) often presents with intermittent bloody diarrhea, recurrent abdominal pain, and weight loss. Patients with these symptoms should be referred for diagnostic colonoscopy. A fecal calprotectin level of 250 mcg per g or greater suggests this condition.

Bleeding from ischemic colitis presents with bloody diarrhea and acute abdominal pain disproportional to physical examination findings in patients with risk factors for cardiovascular disease. These patients should be referred for urgent diagnostic colonoscopy. Computed tomographic angiography may also be ordered to assess vascular flow to the bowel.

Bleeding associated with colon cancer is typically painless, with intermittent episodes of hematochezia, bright red rectal bleeding, or dark (maroon or melena) stool in addition
to bowel habit changes and unintentional weight loss. These patients should be referred for diagnostic colonoscopy.\(^2\)

Diverticular bleeding is often painless with an acute onset in patients with a history of diverticular disease. These patients should be transferred to the emergency department for an expedited workup because these bleeds can often be severe.\(^2,14\)

Postpolypectomy bleeding presents with painless bleeding within 30 days of a polypectomy or biopsy. These patients should be transferred to the emergency department for hospital admission and repeat colonoscopy.

**INPATIENT EVALUATION**

Patients with risk factors for moderate to severe bleeding (e.g., at least two comorbid conditions, heart rate greater than 100 beats per minute [bpm], systolic blood pressure [SBP] less than 115 mm Hg, skin or conjunctival pallor, decreased...
Lower GI bleeding should undergo further evaluation and may require hospital admission. Laboratory testing for these patients should include a complete blood count, measurement of serum electrolytes, coagulation studies, and blood type and screen/cross.

An endoscopic clinician should be consulted for hemodynamically unstable patients (SBP less than 115 mm Hg or heart rate greater than 100 bpm) with hematochezia to evaluate for an upper GI source. Nasogastric lavage is only minimally beneficial in assessing for upper GI bleeding and is not recommended.

Similar to most outpatient evaluations for lower GI bleeding, colonoscopy is preferred for inpatient evaluation. The American College of Gastroenterology recommends that colonoscopy be performed as soon as the patient is hemodynamically stable and has completed adequate bowel preparation. This recommendation is supported by two meta-analyses concluding that early colonoscopy (within 24 hours of presentation) does not improve mortality, need for surgical intervention or blood transfusions, or rates of rebleeding or adverse events. However, it may be associated with more therapeutic interventions. There are conflicting data on its effects on the length of hospitalization and improved identification of the bleeding source.

Computed tomographic angiography can guide therapy in patients who are not candidates for colonoscopy. This imaging modality has a high specificity (91.2%) for detecting stigmata (i.e., visible evidence during endoscopy of localized recent bleeding) in patients with diverticular disease. However, it has not been shown to improve patients’ clinical course, which is why it is not recommended as a first-line modality for evaluation.

Technetium Tc 99m-labeled red blood cell scintigraphy should rarely be used.
LOWER GI BLEEDING

used routinely, but can be considered if other assessment options have been ineffective and the patient is hemodynamically stable with persistent bleeding. The sensitivity of this test ranges from 25% to 90%, and a minimum blood flow of 0.1 mL per minute is required to effectively localize bleeding.18

If the patient remains hemodynamically unstable despite resuscitative efforts, surgical consultation is warranted.

Management

OUTPATIENT MANAGEMENT

Most cases of lower GI bleeding are self-limited and can be managed in an outpatient capacity.28

Internal hemorrhoids grades I to III are amenable to in-office procedures with banding or infrared photocoagulation. Fiber supplementation alone decreases bleeding by 50%.15 Banding has greater long-term success rates than infrared photocoagulation, but the latter confers greater pain improvement. Symptomatic grade III or grade IV hemorrhoids likely will require hemorrhoidectomy by a general surgeon.15

Therapy for infectious colitis is based on the suspected or confirmed pathogen. Table 2 lists specific treatment regimens for common pathogens.18-20

Angiodysplasia self-resolves in 40% to 45% of cases.18 Endoscopic argon plasma coagulation is first-line treatment for persistent bleeding.18 Second-line treatment is direct contact thermal electrocautery (including argon plasma coagulation) with possible endoclip placement. When argon plasma coagulation is used, it is associated with a 7% to 15% recurrence rate.18 Long-term treatment with lanreotide (Somatuline) improves hemoglobin levels and decreases hospitalization time and number of endoscopies and blood/iron transfusions in patients with angiodysplasia or obscure gastrointestinal bleeding.29,30 Hormone therapy (ethinyl estradiol and norethisterone) has no clear benefit in reducing the number of bleeds or transfusion episodes in patients with angiodysplasia.18,31

Acute IBD presenting with bloody diarrhea is correlated with an isolated proctitis flare and responds well to rectal 5-aminosalicylic acid derivatives (mesalamine suppositories) with or without corticosteroids.22 A small randomized controlled trial showed that wheatgrass juice significantly improved rectal bleeding in patients with IBD.32

Patients undergoing outpatient treatment who have recurrent bleeding or hemodynamic instability require hospitalization for stabilization and urgent treatment.

INPATIENT MANAGEMENT

Patients who are hemodynamically unstable require immediate resuscitation. Initial management should include continuous monitoring (telemetry, pulse oximetry, frequent blood pressure measurements), placement of two large-bore peripheral intravenous catheters, and intravenous fluid administration. Critically ill patients can receive normal saline or balanced crystalloids (e.g., lactated Ringer solution); a recent meta-analysis demonstrated no difference in mortality, acute kidney injury, or need for renal replacement therapy.8 Resuscitation goals include a heart rate less than 100 bpm and a SBP consistently higher than 115 mm Hg.2,9

Blood transfusions should be performed to maintain the hemoglobin level above 7 g per dL (70 g per L) in nonacutely or minimally bleeding patients. In contrast, blood transfusions should be initiated in patients with a large quantity of

TABLE 2

<table>
<thead>
<tr>
<th>Organism</th>
<th>History</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>Campylobacter</em></td>
<td>Ingestion of undercooked poultry</td>
<td>Azithromycin (Zithromax), 500 mg per day for 3 to 5 days</td>
</tr>
<tr>
<td><em>Entamoeba histolytica</em></td>
<td>Travel to endemic areas (e.g., tropical Africa, Asia, Latin America)</td>
<td>Metronidazole (Flagyl), 750 mg 3 times per day for 5 to 10 days plus Paromomycin, 25 to 35 mg per kg per day in 3 divided doses for 5 to 10 days</td>
</tr>
<tr>
<td><em>Salmonella</em></td>
<td>Ingestion of contaminated foods (e.g., eggs, poultry); can be spread by pets (e.g., turtles, snakes)</td>
<td>Supportive care</td>
</tr>
<tr>
<td>Shiga toxin-producing <em>Escherichia coli</em></td>
<td>Ingestion of undercooked ground beef</td>
<td>Supportive care</td>
</tr>
<tr>
<td><em>Shigella</em></td>
<td>Exposure to surfaces or ingestion of food or water contaminated with infected fecal matter</td>
<td>Ciprofloxacin, 500 mg 2 times per day for 3 days</td>
</tr>
</tbody>
</table>

Information from references 18-20.
active bleeding and inadequate vital sign response to intravenous fluid replacement when the hemoglobin level drops below 9 g per dL (90 g per L).^{2,16}

Once a patient is hemodynamically stable, colonoscopy should be performed after adequate bowel preparation. The recommended bowel preparation consists of 4 to 6 L of polyethylene glycol or equivalent for three to four hours until excrement is clear of blood and stool.^{2,3,3} The use of a nasogastric tube to administer the bowel preparation is recommended for patients who cannot tolerate it orally. Aspiration risk should be considered when using this technique.^{3,33} Colonoscopists use a variety of techniques to treat bleeding based on the identified source, available resources, and clinician preference. Techniques include therapeutic banding and clipping, argon plasma coagulation, direct contact thermal cauterization, and epinephrine injection (1:10,000 or 1:20,000 dilution with saline).^{3}

Surgery should be considered for patients with significant bleeding when all other strategies have failed, and ideally after a clear source of bleeding has been identified.^{2,18}

**Special Considerations**

Percutaneous catheter embolization should be considered for patients who are high-risk surgical candidates, do not respond to hemodynamic resuscitation, and are unable to tolerate bowel preparation for urgent colonoscopy. Success rates for this procedure have been reported as high as 80% to 90%.^{3,3} However, it is also associated with a 5% to 9% rate of severe adverse events, including hematomas, arterial dissections, pseudoaneurysm, and, rarely, intestinal necrosis.^{3}

Embolization is most effective in patients with poorly controlled diverticular bleeding, with a 15% rebleeding rate compared with 40% for nondiaverticular etiologies.^{3,3}

The use of oral or topical tranexamic acid for the treatment of lower GI bleeding is controversial. A recent randomized controlled trial and a retrospective cohort study failed to demonstrate statistically significant improved clinical outcomes (mortality, transfusion rates, time to first endoscopic procedure).^{11,12} There are currently larger active trials that may provide further information.^{34}

After a patient has experienced a lower GI bleed, a multidisciplinary team approach, including input from specialists involved in the patient’s care, is recommended to minimize the risk of recurrent bleeding and maximize treatment of comorbidities.^{2,14} Aspirin should typically be continued for secondary prophylaxis of cardiovascular disease, as should dual antiplatelet therapy in patients who have had an acute coronary event in the past 90 days or placement of a coronary stent in the past 30 days.^{2} Nonaspirin nonsteroidal anti-inflammatory drugs should be avoided in patients with lower GI bleeding from diverticular disease or angiodysplasia.^{2,13,14} Antiplatelet therapy is associated with an increased risk of recurrent diverticular bleeding. However, anticoagulation therapy does not increase the risk of future diverticular bleeding and is associated with an increased risk of ischemic stroke when discontinued.^{14}

**Data Sources:** Multiple searches were performed in Essential Evidence, PubMed, the Cochrane database, and Google Scholar using the key words lower gastrointestinal bleed, infectious diarrhea, diverticula, angiodysplasia, hemorrhoids, ulcerative colitis,
tr烷amic acid, and balanced fluid resuscitation. Search dates: October 2018 to December 2019.

The opinions and assertions contained herein are those of the authors and are not to be construed as official or as reflecting the views of the Uniformed Services University of the Health Sciences, U.S. Air Force Medical Department, the Air Force at large, or the Department of Defense.

The Authors
MATTHEW K. HAWKS, MD, is an assistant professor at the Uniformed Services University of the Health Sciences, Bethesda, Md.

JENNIFER E. SVARVERUD, DO, is a core faculty member of the Nellis Family Medicine Residency at the Mike O’Callaghan Military Medical Center at Nellis Air Force Base, Nev.

Address correspondence to Matthew K. Hawks, MD, 4301 Jones Bridge Rd., Bethesda, MD 20814 (email: matthewkhawks@gmail.com). Reprints are not available from the authors.

References